Proactive Investors - Run By Investors For Investors

BB Healthcare Trust delivering capital growth and dividends

BBH owns stock in 27 businesses after offloading shares in five companies
scientist using a pipette
The right prescription for growth - the company's focus is on the smaller innovative, research-driven businsses

BB Healthcare Trust PLC (LON:BBH) is run by the management team behind the hugely successful BB Biotech Investment Trust, which has delivered a compound return of 15% annually since its inception 23 years ago.

The new trust has a more expansive remit than its bigger brother, but there is a very rigid internal discipline to stock-picking.

The fund has a cap of 35 companies in which it can invest. And while it takes stakes in specific businesses it does so to garner exposure to investment themes that are rigorously assessed to drive innovation and value.

BBH holds stock in 27 companies

Currently, it owns stock in 27 businesses after closing off positions in Amgen, Lundbeck, Mallinckrodt, Perrigo and Vectura.

The performances varied – the total return for Amgen was 21%, while Lundbeck’s was 44%. Mallinckrodt by contrast lost more than 50%. Vectura and Perrigo were also disappointing investments.

The wider portfolio performed well. BBH’s net asset value was up 2.31% in November and is ahead almost 16% in the year to date. The shares, up around 16% on their listing price back last December, are trading at a modest premium to the net asset value (NAV).

Many of BBH’s investee companies are in the US, just because it is the global hub for the industry and the capital used to bankroll nascent technologies.

Large-caps off the menu

It eschews the big conglomerates such as AstraZeneca, GlaxoSmithKline and Pfizer because of their growth prospects and lack of focus, concentrating on the innovative, fleeter footed small- and mid-caps.

“Many of you will be very aware of our less-than-favourable views of large-cap pharma. This is a considered view, borne of the demonstrably low R&D productivity showed by these companies,” BBH said in its latest newsletter.

“Most of the interesting new products are in-licensed or acquired and we prefer to own the biotechnology companies such products are typically sourced from.”

While the multinationals are largely off the menu, the one thing the smaller firms don’t traditionally provide is a steady dividend.

Dividend payments 

BBH corrects that by making a payout from the company’s net asset value.

Earlier this month it set out its plans by saying it is targeting a total pay-out of 4p per share – with a 2p per share interim payment earmarked for July.

It paid out 1.75p per share as an interim dividend earlier this year, and a further 1.75p final dividend is due for the year ended 30 November.

The divi marks it out in the sector as does a mechanism called a redemption option under which BBH can efficiently return capital to investors if they desire it.

IN-DEPTH: Capital Network research on BBH 

There are a number of advantages to operating this system. It means small investors aren’t at the mercy of the market-makers and their often bafflingly wide spreads.

The redemption option also works well for the big, institutional investors, offering the chance to get into the stock in scale and exit without being murdered.

In other words it promotes liquidity. And while BBH isn’t the first to offer this entry and exit, it is a trendsetter in the world of healthcare.

View full BBH profile View Profile

BB Healthcare Trust PLC Timeline

Big Picture
February 14 2018

Related Articles

trading screen
February 14 2018
Chairman, Professor Justin Stebbing, said he hoped 2018 would be driven more by stock fundamentals

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use